NASDAQ:NVCR NovoCure (NVCR) Stock Price, News & Analysis $12.46 +0.55 (+4.64%) As of 03:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About NovoCure Stock (NASDAQ:NVCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NovoCure alerts:Sign Up Key Stats Today's Range$11.96▼$12.4550-Day Range$10.90▼$18.4652-Week Range$10.87▼$34.13Volume756,504 shsAverage Volume1.21 million shsMarket Capitalization$1.39 billionP/E RatioN/ADividend YieldN/APrice Target$28.79Consensus RatingModerate Buy Company Overview NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. Read More NovoCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreNVCR MarketRank™: NovoCure scored higher than 82% of companies evaluated by MarketBeat, and ranked 195th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingNovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageNovoCure has only been the subject of 3 research reports in the past 90 days.Read more about NovoCure's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for NovoCure are expected to decrease in the coming year, from ($1.30) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovoCure is -7.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovoCure is -7.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoCure has a P/B Ratio of 3.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NovoCure's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.27% of the float of NovoCure has been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NovoCure has recently increased by 5.88%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovoCure does not currently pay a dividend.Dividend GrowthNovoCure does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.15 Percentage of Shares Shorted5.27% of the float of NovoCure has been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NovoCure has recently increased by 5.88%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.38 News SentimentNovoCure has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for NovoCure this week, compared to 5 articles on an average week.Search Interest4 people have searched for NVCR on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows1 people have added NovoCure to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, NovoCure insiders have bought more of their company's stock than they have sold. Specifically, they have bought $231,800.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.52% of the stock of NovoCure is held by insiders.Percentage Held by Institutions84.61% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NovoCure's insider trading history. Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address NVCR Stock News HeadlinesChristoph Brackmann Buys 20,000 Shares of NovoCure Limited (NASDAQ:NVCR) StockJuly 31, 2025 | insidertrades.comNovoCure Limited (NASDAQ:NVCR) Receives $28.79 Average PT from AnalystsAugust 21 at 3:45 AM | americanbankingnews.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 22 at 2:00 AM | Brownstone Research (Ad)Novocure submits Tumor Treating Fields therapy premarket approval applicationAugust 20 at 6:04 PM | msn.comNovocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic CancerAugust 20 at 6:04 PM | finance.yahoo.comLeerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR)August 13, 2025 | msn.comNovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain AheadAugust 1, 2025 | seekingalpha.comNovoCure's Wearable Oncology Edge And Compelling ValuationJuly 30, 2025 | seekingalpha.comSee More Headlines NVCR Stock Analysis - Frequently Asked Questions How have NVCR shares performed this year? NovoCure's stock was trading at $29.80 at the start of the year. Since then, NVCR shares have decreased by 59.2% and is now trading at $12.1550. How were NovoCure's earnings last quarter? NovoCure Limited (NASDAQ:NVCR) released its quarterly earnings results on Thursday, July, 24th. The medical equipment provider reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. The company's revenue was up 5.6% compared to the same quarter last year. Read the conference call transcript. Who are NovoCure's major shareholders? Top institutional investors of NovoCure include Soleus Capital Management L.P. (6.18%), Geode Capital Management LLC (2.19%), Balyasny Asset Management L.P. (2.03%) and Marshall Wace LLP (1.27%). Insiders that own company stock include Wilhelmus Cm Groenhuysen, Ashley Cordova, W Anthony Vernon, Frank X Leonard, Christoph Brackmann, Pritesh Shah, Michal Nath Puri, Uri Weinberg, Asaf Danziger and Mukund Paravasthu. View institutional ownership trends. How do I buy shares of NovoCure? Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NovoCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that NovoCure investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Chembio Diagnostics (CEMI), Tesla (TSLA), Advanced Micro Devices (AMD) and Intel (INTC). Company Calendar Last Earnings7/24/2025Today8/22/2025Next Earnings (Estimated)10/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolNASDAQ:NVCR CIK1645113 Webwww.novocure.com Phone441534756700FaxN/AEmployees1,488Year Founded2000Price Target and Rating Average Price Target for NovoCure$28.79 High Price Target$38.00 Low Price Target$14.50 Potential Upside/Downside+141.7%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$168.63 million Net Margins-27.13% Pretax Margin-22.54% Return on Equity-47.74% Return on Assets-13.79% Debt Debt-to-Equity Ratio0.28 Current Ratio1.45 Quick Ratio1.39 Sales & Book Value Annual Sales$605.22 million Price / Sales2.20 Cash FlowN/A Price / Cash FlowN/A Book Value$3.13 per share Price / Book3.81Miscellaneous Outstanding Shares111,800,000Free Float105,628,000Market Cap$1.33 billion OptionableOptionable Beta0.61 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:NVCR) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.